Delving into the Latest Updates on Sichuan Credit Pharmaceutical Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Sichuan Credit Pharmaceutical Co., Ltd. is a company that specializes in creating, producing, and marketing goods associated with the central nervous system. Their offerings include capsules, tablets, freeze-dried powder injections, water injections, anti-tumor solid preparations, and traditional Chinese medicines. The company was established on April 20, 2000 and is based in Luzhou, China.

Tags

Nervous System Diseases

Other Diseases

Immune System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	2
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

5-HT1A receptor(Serotonin 1a (5-HT1a) receptor)	1
ADRA2(Adrenergic receptors alpha-2)	1

本试验旨在研究单次空腹和餐后口服四川科瑞德制药股份有限公司研制、生产的丙戊酸钠缓释片（I）〔0.5g（以丙戊酸钠计）〕的药代动力学特征；以赛诺菲（杭州）制药有限公司生产的丙戊酸钠缓释片（I）〔德巴金®，0.5g（以丙戊酸钠计）〕为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性，并评价四川科瑞德制药股份有限公司生产的丙戊酸钠缓释片（I）〔0.5g（以丙戊酸钠计）〕的安全性。

[Translation]

This study aims to study the pharmacokinetic characteristics of sodium valproate sustained-release tablets (I) [0.5 g (calculated as sodium valproate)] developed and produced by Sichuan Crede Pharmaceutical Co., Ltd. after single oral administration on an empty stomach or after a meal; using sodium valproate sustained-release tablets (I) [Depakin®, 0.5 g (calculated as sodium valproate)] produced by Sanofi (Hangzhou) Pharmaceutical Co., Ltd. as the reference preparation, compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, evaluate the human bioequivalence of the two preparations, and evaluate the safety of sodium valproate sustained-release tablets (I) [0.5 g (calculated as sodium valproate)] produced by Sichuan Crede Pharmaceutical Co., Ltd.

Start Date09 Apr 2024

Sponsor / Collaborator

Sichuan Credit Pharmaceutical Co., Ltd.

CTR20233326 / CompletedNot Applicable

盐酸替扎尼定口服溶液人体药代动力学比较研究（餐后）

[Translation] Comparative study on the pharmacokinetics of tizanidine hydrochloride oral solution in humans (postprandial)

本试验旨在研究四川科瑞德制药股份有限公司研制、生产的盐酸替扎尼定口服溶液（100 ml:40 mg，以C9H8ClN5S计）的药代动力学特征；以Covis Pharma生产的盐酸替扎尼定片（Zanaflex®，4 mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体药代动力学差异，同时评估受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

The purpose of this study was to study the pharmacokinetic characteristics of tizanidine hydrochloride oral solution (100 ml: 40 mg, calculated as C9H8ClN5S) developed and produced by Sichuan Koruide Pharmaceutical Co., Ltd.; using tizanidine hydrochloride tablets (Zanaflex®, 4 mg) produced by Covis Pharma as the reference preparation, compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, evaluate the difference in human pharmacokinetic between the two preparations, and evaluate the safety of the test preparation and the reference preparation in healthy subjects.

Start Date06 Nov 2023

Sponsor / Collaborator

Sichuan Credit Pharmaceutical Co., Ltd.

CTR20232837 / CompletedNot Applicable

健康受试者在空腹和高脂餐后给药条件下，单次口服奥卡西平口服混悬液的随机、开放、三周期、三序列、部分重复交叉生物等效性试验

[Translation] A randomized, open-label, three-period, three-sequence, partially repeated crossover bioequivalence study of a single oral dose of oxcarbazepine oral suspension in healthy subjects under fasting and high-fat meal conditions

以药代动力学参数为终点指标，比较空腹和高脂餐后给药条件下，四川科瑞德制药股份有限公司生产的奥卡西平口服混悬液与Novartis Pharma Schweiz AG原研进口的奥卡西平口服混悬液（商品名：曲莱®/Trileptal®）在健康成年人群中吸收程度和速度的差异，对两制剂的生物等效性进行评价，并评价空腹和高脂餐后给药条件下，四川科瑞德制药股份有限公司生产的奥卡西平口服混悬液在健康成年人群中的安全性。

[Translation]

Using pharmacokinetic parameters as endpoints, the differences in absorption extent and rate between oxcarbazepine oral suspension produced by Sichuan Crede Pharmaceutical Co., Ltd. and oxcarbazepine oral suspension originally developed and imported by Novartis Pharma Schweiz AG (trade name: Trileptal®/Trileptal®) in healthy adults were compared under fasting and high-fat meal administration conditions, and the bioequivalence of the two preparations was evaluated. The safety of oxcarbazepine oral suspension produced by Sichuan Crede Pharmaceutical Co., Ltd. in healthy adults under fasting and high-fat meal administration conditions was evaluated.

Start Date07 Oct 2023

Sponsor / Collaborator

Sichuan Credit Pharmaceutical Co., Ltd.

100 Clinical Results associated with Sichuan Credit Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Sichuan Credit Pharmaceutical Co., Ltd.

Login to view more data

11

Literatures (Medical) associated with Sichuan Credit Pharmaceutical Co., Ltd.

12 Sep 2024·The Journal of Physical Chemistry B

Structural Models of Human Norepinephrine Transporter Ensemble Reveal the Allosteric Sites and Ligand-Binding Mechanism

Article

Author: Li, Yinghong ; Xue, Weiwei ; Liu, Zerong ; Luo, Ding ; Zhang, Yang ; Wu, Haibo

The norepinephrine transporter (NET) plays a pivotal role in recycling norepinephrine (NE) from the synaptic cleft. However, the structures referring to the conformational heterogeneity of NET during the transport cycle remain poorly understood. Here, three structural models of NE bound to the orthosteric site of NET in outward-open (OO_holo), outward-occluded (OC_holo), and inward-open (IO_holo) conformations were first obtained using the multistate structures of serotonin transporter as templates and further characterized through Gaussian-accelerated molecular dynamics and free energy reweighting. Analysis of the structures revealed eight potential allosteric sites on the functional-specific states of NET. One of the pharmacologically relevant pockets located at the extracellular vestibule was further verified by simulating the binding behaviors of a clinical trial drug χ-MrIA that is allosterically regulating NET. These structural and energetic insights into NET advanced our understanding of NE reuptake and paved the way for discovering novel molecules targeting the allosteric sites.

01 Aug 2024·Bioorganic & Medicinal Chemistry Letters

Design, synthesis, and biological evaluation of new bis-benzylisoquinoline-based analogues as potential neuromuscular blocking agents

Article

Author: Chen, Gang ; Song, Hao ; Gan, Yu ; Fu, Lin ; Qin, Yong ; Liu, Xiaofeng ; Ke, Bowen ; Chen, Chen ; Zhao, Yi

Neuromuscular blocking agents (NMBAs) are widely used in anesthesia for intubation and surgical muscle relaxation. Novel atracurium and mivacurium derivatives were developed, with compounds 18c, 18d, and 29a showing mivacurium-like relaxation at 27.27 nmol/kg, and 15b, 15c, 15e, and 15h having a shorter duration at 272.7 nmol/kg. The structure-activity and configuration-activity relationships of these derivatives and 29a's binding to nicotinic acetylcholine receptors were analyzed through molecular docking. Rabbit trials showed 29a has a shorter duration compared to mivacurium. This suggests that linker properties, ammonium group substituents, and configuration are crucial for NMBA activity and duration, with compound 29a emerging as a potential ultra-short-acting NMBA.

01 Jun 2024·Computers in Biology and Medicine

DTNPD: A comprehensive database of drugs and targets for neurological and psychiatric disorders

Article

Author: Li, Yinghong ; Wen, Lu ; Bai, Mingze ; Luo, Ding ; Liu, Zerong ; Xue, Weiwei ; Tong, Zhuohao ; Jin, Xiaojie

In response to the shortcomings in data quality and coverage for neurological and psychiatric disorders (NPDs) in existing comprehensive databases, this paper introduces the DTNPD database, specifically designed for NPDs. DTNPD contains detailed information on 30 NPDs types, 1847 drugs, 514 drug targets, 64 drug combinations, and 61 potential target combinations, forming a network with 2389 drug-target associations. The database is user-friendly, offering open access and downloadable data, which is crucial for network pharmacology studies. The key strength of DTNPD lies in its robust networks of drug and target combinations, as well as drug-target networks, facilitating research and development in the field of NPDs. The development of the DTNPD database marks a significant milestone in understanding and treating NPDs. For accessing the DTNPD database, the primary URL is http://dtnpd.cnsdrug.com, complemented by a mirror site available at http://dtnpd.lyhbio.com.

100 Deals associated with Sichuan Credit Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Sichuan Credit Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

1

NDA/BLA

Login to view more data